When was AVANT Immunotherapeutics founded?

AVANT Immunotherapeutics was founded in 1998.

Where is AVANT Immunotherapeutics located?

AVANT Immunotherapeutics is headquartered in Needham, United States.

Who is the current CEO of AVANT Immunotherapeutics?

Una Ryan of AVANT Immunotherapeutics.

Where does AVANT Immunotherapeutics rank among its competitors?

AVANT Immunotherapeutics ranks 148th amongst 201 active competitors, of which 55 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Basilea, which secured $13.3M in May, 2026.

Who are the top competitors of AVANT Immunotherapeutics?

AVANT Immunotherapeutics' top competitors include HOOKIPA Pharma, Bharat Biotech and Valneva. Among them, Basilea secured the most recent funding round in May, 2026.

AVANT Immunotherapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Avant Immunotherapeutics is discovering and developing vaccines and therapeutics that harness the human immune system to prevent and treat disease. AVANT’s bacterial vector delivery technologies offer the potential for a new generation of vaccines. AVANT has three commercialized products, including Rotarix for the treatment of rotavirus and two human food safety vaccines for reducing salmonella infection in chickens and eggs. AVANT also has four product candidates in its development pipeline, an anti-inflammatory agent, TP10, and three candidates based on its oral, rapidly-protecting, single-dose and temperature-stable vaccine technology, including combination vaccines for travelers, the military, and global health needs.

Key Metrics

Founded Year

1998

Location

Needham, United States

Stage

Public

Investors

Phase4 Partners & 2 more

Ranked

148^th among 201 active competitors

Similar Companies

HOOKIPA Pharma & 256 more

Exit Details

Public

View AVANT Immunotherapeutics' full profile

AVANT Immunotherapeutics got listed on Oct 01, 2008.

Click here to take a look at AVANT Immunotherapeutics's IPO in detail

AVANT Immunotherapeutics is a funded company. AVANT Immunotherapeutics has 3 institutional investors.

View details of AVANT Immunotherapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AVANT Immunotherapeutics include HOOKIPA Pharma, Bharat Biotech and Valneva. Here is the list of Top 10 competitors of AVANT Immunotherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	69/100
2nd	Bharat Biotech 1996, Hyderabad (India), Early Stage	Manufacturer of vaccines and bio-therapeutic products	$13.7M	ICICI Venture, IFC & 25 others	68/100
3rd	Valneva 1999, Lyon (France), Public	Developer of prophylactic vaccines for infectious diseases	$114M	Phase4 Partners, Eiffel Investment Group ... & 13 others	67/100
4th	Insmed 1999, Bridgewater (United States), Public	Developer of small molecule inhibitors for rare lung diseases	-	Foresite Capital, Quaker Partners Management ... & 13 others	66/100
5th	Evofem 2009, San Diego (United States), Public	Developer of sexual and reproductive health therapeutics	$100M	mercerstcap.com, Aditx Therapeutics & 10 others	65/100
6th	Stallergenes Greer 2013, London (United Kingdom), Acquired	Developing allergen immunotherapy (vaccine) for respiratory allergies	-	Waypoint Capital, B-FLEXION	62/100
7th	Basilea 1999, Basel (Switzerland), Public	Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases	-	Athyrium Capital Management, Medical Countermeasures ... & 2 others	59/100
8th	Centauri Therapeutics 2014, Kent (United Kingdom), Series A	Developer of immunotherapeutics to treat infectious diseases	$73M	Boehringer Ingelheim Venture Fund, REPAIR Impact Fund ... & 32 others	58/100
9th	Eubiologics 2012, Seoul (South Korea), Public	Company providing customized services for development and manufacturing biologics from both mammalian cell and microbial-based systems.	$7.5M	IMM Investment, Global Health Investment Fund ... & 8 others	56/100
10th	Curevo 2017, Seattle (United States), Series B	Developer of non-mRNA adjuvanted subunit vaccines for infectious disease prevention	$196M	RA Capital Management, Janus Henderson Investors ... & 9 others	56/100
148th	AVANT Immunotherapeutics 1998, Needham (United States), Public	Vaccines based on its bacterial vector technologies for infectious diseases.	-	Phase4 Partners, Axiom Venture Partners & 1 others	25/100